Morgan Lewis Advises SV Health Investors on EpiVax Acquisition

BOSTON, April 2, 2026: Morgan Lewis advised SV Health Investors (SVHI), a healthcare and life sciences–focused private investment firm, on the acquisition of EpiVax Inc.

SVHI manages more than $2.0 billion across multiple investment strategies in the healthcare and life sciences sectors. EpiVax is a bioanalytical contract research organization (CRO) specializing in immunogenicity risk assessments for pharmaceutical and biotech companies.

Morgan Lewis partners Greer Longer and Mark Stein and associates Matthew Sherman and Jack Salkowsky advised SVHI.

For more, read SVHI’s announcement.